TY - JOUR
T1 - Opinion
T2 - miRNAs – The new wave of molecular cancer therapeutics
AU - Lopez-Bertoni, Hernando
AU - Laterra, John
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of Health (NIH) [1R01NS096754-01A1 (Laterra) and 1R01NS110087-01A1 (Laterra)]. John Laterra, MD, PhD and Hernando Lopez-Bertoni, PhD contributed equally to the manuscript.
Publisher Copyright:
© 2021
PY - 2021/6
Y1 - 2021/6
N2 - Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.
AB - Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.
UR - http://www.scopus.com/inward/record.url?scp=85102264534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102264534&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2021.101064
DO - 10.1016/j.tranon.2021.101064
M3 - Article
C2 - 33721829
AN - SCOPUS:85102264534
SN - 1936-5233
VL - 14
JO - Translational Oncology
JF - Translational Oncology
IS - 6
M1 - 101064
ER -